Graf Acquisition Corp IV

Graf Acquisition Corp. IV is a blank check company, which was formed for the purpose of effecting into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities. The firm's target business candidates include investment bankers and investment professionals. The company was founded on January 28, 2021 and is headquartered in The Woodlands, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NKGen Biotech, Inc. is a clinical-stage biotechnology company, which focuses on the development and commercialization of innovative autologous, allogeneic, and CAR-NK cell therapies utilizing a proprietary SNK platform. Its product candidates are based on a proprietary manufacturing and cryopreservation process which produces SNK cells that have high potency as defined by parameters such as cytotoxicity, cytokine production, and activating receptor expression. The company was founded by Sangwoo Park in 2017 and is headquartered in Santa Ana, CA.

THE WOODLANDS, Texas , Sept. 22, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 20, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting").

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023

THE WOODLANDS, Texas , Sept. 14, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 13, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting").

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023

THE WOODLANDS, Texas , Sept. 11, 2023 /PRNewswire/ -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the "Company" or "Graf"), announced today that on September 8, 2023, it adjourned, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the "Business Combination") with NKGen Biotech, Inc. ("NKGen" and such special meeting, the "Special Meeting").

Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023

THE WOODLANDS, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Graf Acquisition Corp. IV (NYSE: GFOR, GFOR-UN, GFOR-WT) (the “Company” or “Graf”), announced today that it intends to adjourn, without conducting any business, the special meeting of its stockholders to be held to approve, among other things, the previously announced business combination (the “Business Combination”) with NKGen Biotech, Inc. (“NKGen” and such special meeting, the “Special Meeting”), which is scheduled to occur at 10:00 a.m., Eastern time, on August 30, 2023, and to reconvene the Special Meeting at 10:30 a.m., Eastern time, on September 8, 2023. The Special Meeting will still be held virtually at https://www.cstproxy.com/grafiv/sm2023 .

Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023

SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced the first patient has been dosed in a Phase I, multi-center, open-label, dose-escalation study evaluating its cryopreserved investigational allogeneic blood-derived NK cell therapy (“SNK02”). In October 2022, the Food and Drug Administration allowed NKGen's Phase I SNK02 clinical trial to proceed per its Investigational New Drug application. NKGen previously announced a proposed business combination with Graf Acquisition Corp. IV (NYSE: GFOR.U, GFOR, GFOR.WS).

NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors

Special Meeting of Graf Stockholders to Approve Proposed Business Combination to be Held on August 30, 2023

Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination

SANTA ANA, Calif. and THE WOODLANDS, Texas, Aug. 09, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapies, and Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (“Graf”) today announced that Michael Klowden and Kathleen Scott have been nominated to serve as independent members of the Board of Directors (the “Board”) of the post-business combination company (“New NKGen”). Assuming the director nominees are elected by the stockholders of Graf at the special meeting of its stockholders to be held to approve the business combination between Graf and NKGen (the “business combination”), their appointment will be effective upon the closing of the business combination. The closing of the proposed business combination is expected to occur in the third quarter of 2023.

NKGen Biotech and Graf Acquisition Corp. IV Announce the Nomination of Two Independent Directors for the Board of Directors of the Post-Business Combination Public Company

SANTA ANA, Calif. and THE WOODLANDS, Texas, July 06, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer (“NK”) cell therapies, and Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (“Graf”) will co-host an investor event at the Lotte New York Palace Hotel on July 20, 2023 at 10:00 AM ET.

NKGen Biotech Inc. and Graf Acquisition Corp. IV to Co-Host Investor Event

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV (NYSE: GFOR) (“Graf”), announced today that it has been informed that it currently has received stockholder votes from more than 65% of its stockholders to approve the Extension to September 29, 2023. Graf stockholders will cast their votes to approve the Extension at the special meeting of Graf stockholders to be held on May 22, 2023. As previously announced on April 14, 2023, Graf signed a merger agreement for a business combina.

Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension

SANTA ANA, Calif. and THE WOODLANDS, Texas, April 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer (“NK”) cell therapeutics, and Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (“Graf”), a New York Stock Exchange-listed special purpose acquisition company founded by serial SPAC founder James Graf, along with Sabrina McKee and Tony Kuznik, announced today that they have entered into a definitive agreement (the “Merger Agreement”) for a business combination(the “Business Combination”). Upon the closing of the Business Combination, Graf will be renamed “NKGen Biotech, Inc.” and is expected to be listed on the New York Stock Exchange, NYSE American or Nasdaq under the ticker symbol “NKGN”.

NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV

THE WOODLANDS, Texas--( BUSINESS WIRE )--Graf Acquisition Corp. IV (NYSE: GFOR, GFOR.U, GFOR WS) (the “Company”) today announced that it is withdrawing from the ballot for its special meeting of stockholders to be held on December 21, 2022 (the “Special Meeting”) the proposal to amend the Company's certificate of incorporation to extend the date by which the Company must consummate a business combination from May 25, 2023 to September 29, 2023 (the “Extension Proposal”). The withdrawal of the Extension Proposal has no effect on the three other proposals on the ballot for the Special Meeting. As a result of the withdrawal of the Extension Proposal, the Company will cease to provide stockholders with the opportunity to redeem their shares for a pro rata portion of the funds held in the trust account in connection with the Special Meeting. Any shares already submitted for redemption will be returned to shareholders promptly.

Graf Acquisition Corp. IV Withdraws Extension Proposal

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021

Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

Graf Acquisition Corp. IV Announces Closing of Underwriters' Over-Allotment Option in Connection with its Initial Public Offering

THE WOODLANDS, Texas--(BUSINESS WIRE)--Graf Acquisition Corp. IV Announces Closing of $150 Million Initial Public Offering

News for Graf Acquisition Corp IV Stock (GFOR)